• Recent news

  • Woulgan® to be listed on UK Drug Tariff

    Biotec Pharmacon's wholly owned subsidiary Biotec BetaGlucans has received feedback from the NHS that Woulgan® will be listed on the UK Drug Tariff from January 2018. -This is a key milestone for us because it gives Woulgan access to a major European market. It is also a strong signal to other markets…

    Continue reading

Latest presentation

Third quarter 2017 results

Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 14.4 million (21.1) in the third quarter of 2017, and a negative EBITDA of NOK 7.3 million (-5.9). Woulgan® generated sales of NOK 0.4 million during the third quarter. ArcticZymes had a slight reduction in sales compared to third quarter last year…

View more